Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Cellectar Biosciences (CLRB) Stock Price
News coverage about Cellectar Biosciences (NASDAQ:CLRB) has been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cellectar Biosciences earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.4391148934623 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
- Cellectar Biosciences, Inc. (CLRB) Downgraded by Zacks Investment Research (americanbankingnews.com)
- Watching the Tape Move for Cellectar Biosciences Inc (CLRB) – Evergreen Caller (evergreencaller.com)
- Cellectar Biosciences Inc (CLRB) Seeing Increased Volatility in Session – Stock Press Daily (stockpressdaily.com)
- Boom or Bust? Is there any value in Cellectar Biosciences, Inc. (NASDAQ:CLRB)? – FLBC News (flbcnews.com)
- Edited Transcript of CLRB earnings conference call or presentation 14-Aug-17 9:00pm GMT (finance.yahoo.com)
Cellectar Biosciences (CLRB) opened at 1.51 on Monday. The firm’s 50-day moving average price is $1.55 and its 200-day moving average price is $1.89. The firm’s market cap is $21.02 million. Cellectar Biosciences has a 1-year low of $1.12 and a 1-year high of $3.47.
Cellectar Biosciences (NASDAQ:CLRB) last announced its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.01. Equities research analysts anticipate that Cellectar Biosciences will post ($0.92) earnings per share for the current fiscal year.
CLRB has been the subject of a number of analyst reports. Zacks Investment Research downgraded Cellectar Biosciences from a “hold” rating to a “sell” rating in a research note on Friday. ValuEngine downgraded Cellectar Biosciences from a “sell” rating to a “strong sell” rating in a research note on Tuesday, May 23rd.
ILLEGAL ACTIVITY NOTICE: This news story was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/08/21/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-cellectar-biosciences-clrb-stock-price.html.
Cellectar Biosciences Company Profile
Cellectar Biosciences, Inc, formerly Novelos Therapeutics, Inc, is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform.
Receive News & Stock Ratings for Cellectar Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences Inc. and related stocks with our FREE daily email newsletter.